Graham Parry
Stock Analyst at Citi
(3.00)
# 2,690
Out of 5,125 analysts
242
Total ratings
63.6%
Success rate
2.1%
Average return
Main Sectors:
Stocks Rated by Graham Parry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: GSK GSK plc | Maintained: Hold | 2,100p → 2,050p | 1,917p | +6.94% | 55 | Nov 11, 2026 | |
| SWX: ROP Roche Holding AG | Reiterated: Buy | CHF 440.00 | CHF 401.80 | +9.51% | 6 | Nov 9, 2026 | |
| SWX: NOVN Novartis AG | Reiterated: Buy | CHF 135.00 → CHF 150.00 | CHF 134.48 | +11.54% | 57 | Nov 6, 2026 | |
| LON: AZN AstraZeneca PLC | Reiterated: Buy | 18,900p | 13,884p | +36.13% | 19 | Nov 2, 2026 | |
| EPA: SAN Sanofi | Reiterated: Hold | €85.00 → €80.00 | €85.95 | -6.92% | 40 | Feb 20, 2026 | |
| SNY Sanofi | Reiterated: Buy | n/a | $48.23 | n/a | 17 | Jan 31, 2025 | |
| GSK GSK plc | Reiterated: Sell | $19 | $51.23 | n/a | 23 | Dec 6, 2024 | |
| NVS Novartis AG | Rated: Hold | $118 → $130 | $163.26 | n/a | 17 | Sep 11, 2024 | |
| BME: GRF Grifols, S.A. | Initiated Coverage: Buy | €20.00 | €11.38 | n/a | 1 | Sep 12, 2023 | |
| LON: HLN Haleon plc | Reiterated: Buy | 358p → 618p | 335p | n/a | 2 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $88 | $170.87 | n/a | 1 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $50 | $29.36 | n/a | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $54.07 | n/a | 1 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $34 | $61.08 | n/a | 1 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $3.56 | n/a | 1 | Oct 26, 2017 |
GSK plc
Nov 11, 2026
Maintained: Hold
Price Target: 2,100p → 2,050p
Current: 1,917p
Upside: +6.94%
Roche Holding AG
Nov 9, 2026
Reiterated: Buy
Price Target: CHF 440.00
Current: CHF 401.80
Upside: +9.51%
Novartis AG
Nov 6, 2026
Reiterated: Buy
Price Target: CHF 135.00 → CHF 150.00
Current: CHF 134.48
Upside: +11.54%
AstraZeneca PLC
Nov 2, 2026
Reiterated: Buy
Price Target: 18,900p
Current: 13,884p
Upside: +36.13%
Sanofi
Feb 20, 2026
Reiterated: Hold
Price Target: €85.00 → €80.00
Current: €85.95
Upside: -6.92%
Sanofi
Jan 31, 2025
Reiterated: Buy
Price Target: n/a
Current: $48.23
Upside: n/a
GSK plc
Dec 6, 2024
Reiterated: Sell
Price Target: $19
Current: $51.23
Upside: n/a
Novartis AG
Sep 11, 2024
Rated: Hold
Price Target: $118 → $130
Current: $163.26
Upside: n/a
Grifols, S.A.
Sep 12, 2023
Initiated Coverage: Buy
Price Target: €20.00
Current: €11.38
Upside: n/a
Haleon plc
Mar 7, 2023
Reiterated: Buy
Price Target: 358p → 618p
Current: 335p
Upside: n/a
Mar 3, 2023
Reiterated: Hold
Price Target: $88
Current: $170.87
Upside: n/a
Feb 28, 2023
Reiterated: Hold
Price Target: $50
Current: $29.36
Upside: n/a
Sep 10, 2018
Downgraded: Sell
Price Target: n/a
Current: $54.07
Upside: n/a
Sep 10, 2018
Downgraded: Hold
Price Target: $34
Current: $61.08
Upside: n/a
Oct 26, 2017
Downgraded: Sell
Price Target: n/a
Current: $3.56
Upside: n/a